Diagnosis and treatment of chronic myeloid leukemia in the imatinib mesylate era: Report of the experience at “La Raza” Medical Center in Mexico

Conclusion IM offers long-term OS expectations not seen before with any other therapy, in addition to a good quality of life. However, more than a third of patients require further treatment with a second-generation TKI; consequently, expectations for treatment-free remission and long-term OS are reduced. Timely change to second-generation TKIs could improve such expectations.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research